Rchr
J-GLOBAL ID:201801013149409745   Update date: Jan. 30, 2024

Tamami Morisaki

モリサキ タマミ | Tamami Morisaki
Affiliation and department:
Job title: Lecturer
Other affiliations (1):
  • 臨床医科学専攻  病院講師
Research field  (1): General surgery, pediatric surgery
Research theme for competitive and other funds  (3):
  • 2018 - 2022 Development of the simulation-based training program for women's preventive medicine.
  • 2017 - 2020 Involvement of associating cancer stem cell in breast cancer
  • 2014 - 2018 CONQUEST OF THE SCIRRHOUS GASTRIC CANCER: AUTOPHAGY OF CANCER STEM CELLS AND DEVELOPMENT OF MOLECULAR TARGET
Papers (252):
  • Takada K, Kashiwagi S, Iimori N, Kouhashi R, Yabumoto A, Goto W, Asano Y, Tauchi Y, Morisaki T, Ogisawa K, et al. Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer. BMC cancer. 2023. 23. 1. 224
  • 三浦 拓也, 後藤 航, 高田 晃次, 浅野 有香, 森崎 珠実, 柏木 伸一郎, 高島 勉, 平川 弘聖, 大平 雅一. 局所進行乳癌に対するRhomboid Flapを用いた原発巣切除の長期成績. 癌と化学療法. 2023. 50. 2. 245-247
  • 加藤 きみ佳, 森崎 珠実, 高田 晃次, 後藤 航, 柏木 伸一郎. がん遺伝子パネル検査が治療方針に寄与した両側乳癌の1例. 日本臨床外科学会雑誌. 2023. 84. 2. 265-268
  • Miura T. The Long Term Result of Rhomboid Flap Reconstruction for Locally Advanced Breast Cancer. Gan to kagaku ryoho. Cancer & chemotherapy. 2023. 50. 2. 245-247
  • Takada K, Kashiwagi S, Iimori N, Kouhashi R, Yabumoto A, Goto W, Asano Y, Tauchi Y, Ogisawa K, Morisaki T, et al. Prognostic Impact of Smoking on Bevacizumab Combination Chemotherapy for Advanced Breast Cancer. Anticancer research. 2023. 43. 2. 849-856
more...
MISC (233):
  • Yuka Asano, Shinichiro Kashiwagi, Rika Kouhashi, Koji Takada, Wataru Goto, Sae Ishihara, Yukie Tauchi, Tamami Morisaki, Satoru Noda, Tsutomu Takashima, et al. [A Case of Advanced Breast Cancer with Altered Biology by Eribulin Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy. 2019. 46. 13. 2330-2332
  • Sae Ishihara, Shinichiro Kashiwagi, Yuka Asano, Yukie Tauchi, Tamami Morisaki, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, Kosei Hirakawa, Masaichi Ohira. [A Case of Recurrent Breast Cancer Treated with Local Irradiation Using Leadless Pacemaker Implantation]. Gan to kagaku ryoho. Cancer & chemotherapy. 2019. 46. 13. 1984-1986
  • Sae Ishihara, Naoyoshi Onoda, Satoru Noda, Yuka Asano, Yukie Tauchi, Tamami Morisaki, Shinichiro Kashiwagi, Tsutomu Takashima, Masaichi Ohira. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status. International journal of oncology. 2019. 55. 5. 1069-1076
  • Naoyoshi Onoda, Satoru Noda, Yukie Tauchi, Yuka Asano, Yukina Kusunoki, Sae Ishihara, Tamami Morisaki, Shinichiro Kashiwagi, Tsutomu Takashima, Masaichi Ohira. Continuous intraoperative neuromonitoring for thyroid cancer surgery: A prospective study. Laryngoscope investigative otolaryngology. 2019. 4. 4. 455-459
  • Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Koji Takada, Sae Ishihara, Yukie Tauchi, Tamami Morisaki, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, et al. [A Case of Invasive Ductal Carcinoma with Paget's Disease of the Breast]. Gan to kagaku ryoho. Cancer & chemotherapy. 2018. 45. 13. 1842-1844
more...
Lectures and oral presentations  (350):
  • 進行・再発乳癌における外科治療の意義と適応 局所切除術を施行した乳癌再発症例における予後予測因子の検証
    (日本外科学会定期学術集会抄録集 2023)
  • 腫瘍免疫および内分泌感受性を考慮したHER2陽性乳癌における新たな細分類
    (日本外科学会定期学術集会抄録集 2023)
  • 乳癌術後10年無再発経過後に診断された局所再発症例の検討
    (日本外科学会定期学術集会抄録集 2023)
  • 乳癌術前化学療法における組織マーカー留置の意義
    (日本外科学会定期学術集会抄録集 2023)
  • 乳癌術前化学療法における免疫関連分子(PD-1,PD-L1,PD-L2,LAG-3,TIM-3,OX-40)発現解析
    (日本外科学会定期学術集会抄録集 2023)
more...
Education (2):
  • 2010 - 2014 Osaka City University
  • 1998 - 2004 Osaka Medical College
Professional career (2):
  • 博士(医学) (大阪市立大学)
  • 学士(医学) (大阪医科大学)
Work history (2):
  • 2022/10 - 現在 Osaka Metropolitan University Graduate School of Medicine Department of Clinical Medical Science Lecturer
  • 2022/09 - 現在 Osaka Metropolitan University Graduate School of Medcine Department of Clinical Medical Science Lecturer
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page